Spots Global Cancer Trial Database for peritoneal cancer
Every month we try and update this database with for peritoneal cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT01767675 | Ovarian Cancer Fallopian Tubes... Peritoneal Canc... | Secondary Cytor... Carboplatin Hyp... platinum-based ... platinum-based ... | 21 Years - | Memorial Sloan Kettering Cancer Center | |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | NCT01493505 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | AMG 386 Paclitaxel AMG 386 Placebo Carboplatin | 18 Years - | Amgen | |
| Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | NCT01416038 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | DPX-Survivac low dose cyclop... | 18 Years - | ImmunoVaccine Technologies, Inc. (IMV Inc.) | |
| A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers | NCT02824328 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Uterine Endomet... | 18 Years - | Duke University | ||
| A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | NCT01649336 | Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | MEK162, MEK inh... Paclitaxel, mit... | 18 Years - | Array BioPharma | |
| Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer | NCT03693248 | Ovarian Cancer ... Ovarian Cancer ... Fallopian Tube ... Peritoneal Canc... | Two cycles of n... | 20 Years - 80 Years | Seoul National University Hospital | |
| A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | NCT04022213 | Desmoplastic Sm... Peritoneal Canc... Peritoneal Carc... | 131 I-omburtama... WAP-IMRT | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane | NCT02728622 | Ovarian Cancer Peritoneal Canc... Cancer of the F... | Tamoxifen Chemotherapy | 18 Years - | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | |
| LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer | NCT02668913 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... Gynaecological ... | Diagnostic anal... | 18 Years - | University of Leeds | |
| Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | NCT00856180 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Bevacizumab Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | NCT01188876 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | carboplatin pralatrexate Folic Acid Vitamin B12 Inj... | 18 Years - | Massachusetts General Hospital | |
| A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | NCT00683241 | Ovarian Cancer Peritoneal Canc... | DCVac-L | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | NCT01610206 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Gemcitabine pazopanib | 18 Years - | University of Virginia | |
| AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | NCT01065662 | Endometrial Can... Ovarian Cancer Cervical Cancer Fallopian Tube ... Peritoneal Canc... | temsirolimus cediranib | 18 Years - | Dana-Farber Cancer Institute | |
| TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer | NCT01493505 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | AMG 386 Paclitaxel AMG 386 Placebo Carboplatin | 18 Years - | Amgen | |
| Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer | NCT04701645 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Ovarian Cancer ... Ovarian Cancer ... Fallopian Tube ... Fallopian Tube ... | Microdevice | 18 Years - | Dana-Farber Cancer Institute | |
| Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | NCT00436215 | Ovarian Neoplas... Fallopian Tube ... Primary Periton... | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Choices About Genetic Testing And Learning Your Risk With Smart Technology | NCT06184867 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Breast Cancer Pancreas Cancer Colorectal Canc... Endometrial Can... Prostate Cancer | Relational Agen... Clinical Letter | 18 Years - | Rutgers, The State University of New Jersey | |
| Multi-Centre Observational Study of Maintenance Niraparib in Treatment of Ovarian CanceR | NCT04295577 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Niraparib | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival | NCT04402333 | Ovarian Cancer Ovarian Neoplas... Ovarian Neoplas... Fallopian Tube ... Peritoneal Canc... | Robotic Interva... | 18 Years - | Royal Surrey County Hospital NHS Foundation Trust | |
| Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer | NCT00317772 | Ovarian Cancer Peritoneal Neop... Fallopian Tube ... | Topotecan Gefitinib | - | M.D. Anderson Cancer Center | |
| A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT00753480 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | D4064A | 18 Years - | Genentech, Inc. | |
| Using Aspirin to Improve Immunological Features of Ovarian Tumors | NCT05080946 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Aspirin 325mg Placebo | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Development and Management of Registry in Patients With Gynecologic Cancer in Korea | NCT05912972 | Cervical Cancer Endometrial Can... Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Patient registr... | 18 Years - | Asan Medical Center | |
| Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal Cancer | NCT05792254 | Primary Ovarian... Fallopian Tube ... Peritoneal Canc... | Huaier granule | 18 Years - | Ruijin Hospital | |
| Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer | NCT00529022 | Solid Tumors | Azacitidine Valproic Acid Carboplatin | - | M.D. Anderson Cancer Center | |
| A Study of ZN-c3 in Patients With Ovarian Cancer | NCT04516447 | Solid Tumor Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | ZN-c3 Carboplatin Pegylated lipos... Paclitaxel Gemcitabine Bevacizumab | 18 Years - | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | |
| Quadratus Lumborum Block After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy | NCT05597683 | Cytoreductive S... Hyperthermic In... Peritoneal Canc... | Arm I (QL block... | 19 Years - | Gangnam Severance Hospital | |
| A Study of Long-Term Responders on Olaparib | NCT02489058 | Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | 18 Years - | University Health Network, Toronto | ||
| Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab | NCT01223235 | Fallopian Tubes... Ovarian Cancer Peritoneal Canc... | bevacizumab and... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | NCT03657043 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | tisotumab vedot... | 18 Years - | Seagen Inc. | |
| Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours | NCT00475956 | Neoplasms | AZD2171 AZD0530 | 18 Years - | AstraZeneca | |
| LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer | NCT02668913 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... Gynaecological ... | Diagnostic anal... | 18 Years - | University of Leeds | |
| Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | NCT00318370 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Farletuzumab Chemo Plus Far | 18 Years - | Morphotek | |
| Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer | NCT00431054 | Ovarian Cancer | Perifosine Docetaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) | NCT01968213 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Rucaparib Placebo | 18 Years - | pharmaand GmbH | |
| Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial | NCT01506856 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Paclitaxel(intr... Paclitaxel(intr... | 20 Years - | Gynecologic Oncology Trial & Investigation Consortium | |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy | NCT03593681 | Fallopian Tube ... Ovarian Cancer Ovarian Neoplas... Ovary Cancer Fallopian Tube ... Fallopian Tube ... High Grade Sero... Peritoneal Carc... Peritoneal Neop... Adnexal Mass Ovarian Disease... | Hysteroscopic c... | 18 Years - | Boston Scientific Corporation | |
| Letrozole in Patients With Ovarian Tumors | NCT00505661 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Letrozole | 18 Years - | M.D. Anderson Cancer Center | |
| Accelerating Gastrointestinal Recovery | NCT01704651 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Alvimopan Placebo | 18 Years - | Mayo Clinic | |
| Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | NCT00230542 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Carboplatin Pemetrexed | 18 Years - | Dana-Farber Cancer Institute | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer | NCT00692900 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | intravenous doc... intravenous oxa... | 18 Years - | University of Pittsburgh | |
| Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | NCT01083537 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... Bowel Obstructi... | Cisplatin Paclitaxel | 18 Years - | University Health Network, Toronto | |
| EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | NCT00035100 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... | epothilone b | 18 Years - | Novartis | |
| Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer | NCT00850772 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... | Early post-oper... | 18 Years - | Queensland Centre for Gynaecological Cancer | |
| Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | NCT00856180 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Bevacizumab Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum | NCT01099644 | Peritoneal Canc... | 131 I-8H9 | 1 Year - | Y-mAbs Therapeutics | |
| VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00436501 | Fallopian Tube ... Malignant Tumor... Recurrent Ovari... | docetaxel ziv-aflibercept laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | NCT00910000 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Vorinostat Carboplatin Gemcitabine | 18 Years - | Dana-Farber Cancer Institute | |
| Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | NCT02865811 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Pembrolizumab Pegylated Lipos... | 18 Years - | Dana-Farber Cancer Institute | |
| Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer | NCT02657889 | Neoplasms Triple Negative... Ovarian Cancer Breast Cancer Metastatic Brea... Advanced Breast... Stage IV Breast... Fallopian Tube ... Peritoneal Canc... | niraparib pembrolizumab | 18 Years - | Tesaro, Inc. | |
| VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | NCT00436501 | Fallopian Tube ... Malignant Tumor... Recurrent Ovari... | docetaxel ziv-aflibercept laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib | NCT05887609 | Ovary Cancer Peritoneal Canc... Fallopian Tube ... | Mirvetuximab So... Olaparib | 18 Years - 99 Years | University of Colorado, Denver | |
| MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | NCT05708924 | Cancer Solid Tumor Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | FT538 Enoblituzumab | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | NCT03126812 | Ovarian Cancer ... Peritoneal Canc... Fallopian Tube ... | Carboplatin Paclitaxel Pembrolizumab | 18 Years - | The Netherlands Cancer Institute | |
| Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer | NCT00850772 | Epithelial Ovar... Peritoneal Canc... Fallopian Tube ... | Early post-oper... | 18 Years - | Queensland Centre for Gynaecological Cancer | |
| Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | NCT00517621 | Ovarian Cancer Fallopian Tube ... Peritoneal Neop... | Paclitaxel EPO | 18 Years - | ARCAGY/ GINECO GROUP | |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery | NCT04498117 | Carcinoma, Ovar... Ovarian Neoplas... Ovarian Cancer Ovarian Serous ... Fallopian Tube ... Fallopian Tube ... Fallopian Tube ... Peritoneal Canc... Peritoneal Carc... Peritoneal Neop... | Oregovomab Paclitaxel Carboplatin Placebo Carboplatin | 18 Years - | CanariaBio Inc. | |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | NCT01891344 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | Oral rucaparib | 18 Years - | pharmaand GmbH | |
| A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | NCT00683241 | Ovarian Cancer Peritoneal Canc... | DCVac-L | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Choices About Genetic Testing And Learning Your Risk With Smart Technology | NCT06184867 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Breast Cancer Pancreas Cancer Colorectal Canc... Endometrial Can... Prostate Cancer | Relational Agen... Clinical Letter | 18 Years - | Rutgers, The State University of New Jersey | |
| A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. | NCT00637390 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Alemtuzumab | 18 Years - | University of Michigan Rogel Cancer Center | |
| A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT06087289 | Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... | KAND567 Carboplatin | 18 Years - | Kancera AB | |
| Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis | NCT04122885 | Peritoneal Canc... Chemotherapy-In... | PIPAC with oxal... Cytoreductive s... | 18 Years - | University Hospital Tuebingen | |
| Depression Treatment and Screening in Ovarian Cancer Patients | NCT00515372 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Telephone Couns... Usual Care | 18 Years - | M.D. Anderson Cancer Center | |
| Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | NCT00408070 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... Stage 3 Cancer Stage 4 Cancer | Bevacizumab Carboplatin Paclitaxel | 19 Years - | UConn Health | |
| A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum | NCT04022213 | Desmoplastic Sm... Peritoneal Canc... Peritoneal Carc... | 131 I-omburtama... WAP-IMRT | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer | NCT01591772 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | Neuroimaging & ... Neuroimaging & ... | 21 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| ChemoFx® PRO - A Post-Market Data Collection Study | NCT00669422 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Uterine Neoplas... Endometrial Can... Vaginal Cancer Vulvar Cancer Cervical Cancer | 18 Years - | Precision Therapeutics | ||
| A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT00753480 | Fallopian Tube ... Ovarian Cancer Peritoneal Canc... | D4064A | 18 Years - | Genentech, Inc. | |
| Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00634894 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Femara Placebo | - | M.D. Anderson Cancer Center | |
| Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients | NCT04537702 | Ovarian Cancer,... Peritoneal Canc... Fallopian Tube ... | Streamlined Edu... Traditional Edu... | 18 Years - | Duke University | |
| Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | NCT02022917 | Epithelial Ovar... | Bevacizumab | 20 Years - 75 Years | Chang Gung Memorial Hospital | |
| Post Splenectomy Infections After Surgery for Peritoneal Malignancies (OPSI) | NCT05718726 | Post-Splenectom... Peritoneal Canc... | Questionnaire, ... | 18 Years - 79 Years | Hampshire Hospitals NHS Foundation Trust | |
| Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients | NCT02470299 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... | Ketorolac Placebo | 18 Years - | New Mexico Cancer Care Alliance | |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) | NCT05445778 | Ovarian Cancer Peritoneal Canc... Fallopian Tube ... | Mirvetuximab so... Bevacizumab | 18 Years - | ImmunoGen, Inc. | |
| Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy | NCT00377429 | Ovarian Cancer | catumaxomab | 18 Years - | Neovii Biotech | |
| Choices About Genetic Testing And Learning Your Risk With Smart Technology | NCT06184867 | Ovarian Cancer Fallopian Tube ... Peritoneal Canc... Breast Cancer Pancreas Cancer Colorectal Canc... Endometrial Can... Prostate Cancer | Relational Agen... Clinical Letter | 18 Years - | Rutgers, The State University of New Jersey |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
